Novel compound for treatment of allergy and asthma
CA 2441048 C · Owner: Phadia Ab · Inventors: Adriansson, Jonas; Sperr, Wolfgang R.; Kraft, Dietrich
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE- Fc.epsilon.RI interaction; b) binds to free and cell-bound IgE; and c) is nonanaphylactic.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 28, 2002 and granted December 13, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 28, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 28, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.